Dr. Doug Fisher joined InterWest's life sciences team in 2009, focusing on biopharmaceutical, diagnostic, and medical device investments. He is a board member of Cardiac Dimensions, Gynesonics, Obalon Therapeutics, QuatRx, Sera Prognostics and USDS. Doug also is actively involved in InterWest's investments in Integrated Diagnostics and Invuity.

Prior to joining InterWest, Doug was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including Pearl Therapeutics, Interlace Medical (Acquired by Hologic), and Stromedix. Prior to joining New Leaf, Doug was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area and consulted for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group where he developed product strategies in new disease areas for Remicade.

Doug received an A.B. in economics with honors and distinction and a B.S. in biology with distinction from Stanford where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton where he graduated with honors as a Siebel Scholar and Palmer Scholar.